Technical Data
| Formula | C25H23F3N4O2 |
||||||
| Molecular Weight | 468.47 | CAS No. | 2097262-58-1 | ||||
| Solubility (25°C)* | In vitro | DMSO | 94 mg/mL (200.65 mM) | ||||
| Ethanol | 50 mg/mL (106.73 mM) | ||||||
| Water | Insoluble | ||||||
| In Vivo (Add solvents to the product individually and in order.) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||
Preparing Stock Solutions
Biological Activity
| Description | TVB-3664 is a potent, selective, orally active and reversible inhibitor of fatty acid synthase (FASN) with IC50 of 0.018 M and 0.012 M for human and mouse cell palmitate synthesis, respectively. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro | TVB-3664 induces FASN inhibition with significantly reduced tubulin palmitoylation and mRNA expression. Disrupted microtubule organization in tumour cells is an additional consequence of FASN inhibition. This compound combined with taxane treatment enhances inhibition of in vitro tumour cell growth compared to treatment with either agent alone. |
||||
| In Vivo | In lung, ovarian, prostate, and pancreatic tumour xenograft studies, TVB-3664 inhibits xenograft tumour growth with significantly enhanced anti-tumour activity. Tumour regression is observed in 3 of 6 tumour xenograft models. |
Protocol (from reference)
| Cell Assay: |
|
|---|---|
| Animal Study: |
|
References
|
Sellecks TVB-3664 Has Been Cited by 6 Publications
| The autophagy receptor Ncoa4 controls PPARγ activity and thermogenesis in brown adipose tissue [ bioRxiv, 2025, 2025.02.02.636110] | PubMed: 39974946 |
| De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics [ Nat Commun, 2023, 14(1):1362] | PubMed: 36914626 |
| Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice [ bioRxiv, 2023, 2023.07.05.547848] | PubMed: 37461560 |
| ATP citrate lyase controls hematopoietic stem cell fate and supports bone marrow regeneration [ EMBO J, 2022, e109463] | PubMed: 35229328 |
| Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication [ Nat Metab, 2021, 10.1038/s42255-021-00479-4] | PubMed: 34580494 |
| Metabolomic credentialing of murine carcinogen-induced urothelial cancer [ Sci Rep, 2021, 11(1):22085] | PubMed: 34764423 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.